Previous 10 | Next 10 |
2024-01-30 08:39:35 ET More on Aditx Therapeutics Aditxt announces $6M private placement to fund its working capital Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Aditx Therapeutics Historical earnin...
The global EEG devices market was valued at $1.06 billion in 2022 and is anticipated to expand at a CAGR of 10.2% from 2023 to 2030 Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promisin...
2024-01-18 16:37:30 ET More on Aditx Therapeutics Aditxt announces $6M private placement to fund its working capital Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Aditx Therapeutics Historical earnin...
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, and its subsidiary Pearsanta Inc., have announced the acquisition of MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early-disease and cancer-detection plat...
This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women’s health, spanning endometriosis to ovarian cancer, and in men’s health starting with prostate cancer Aditxt, Inc. (“Aditxt” or the “Company”) (NA...
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an agg...
2024-01-02 12:56:48 ET More on Mid-day movers & stocks. ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Endra Life Sciences Historical earnings da...
2024-01-02 08:46:55 ET More on Aditx Therapeutics Aditxt announces $6M private placement to fund its working capital Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Aditx Therapeutics Historical earnin...
2024-01-02 08:30:21 ET Losers: Corcept Therapeutics CORT -33% in patent battle with Teva . China SXT Pharmaceuticals ( SXTC ) -29% . Sentage Holdings ( SNTG ) -27% . China Green Agriculture ( CGA ) -23% . Aditxt ( ADTX ) -24% . ...
Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) Hearing Pane...
News, Short Squeeze, Breakout and More Instantly...
ADiTx Therapeutics Inc. Company Name:
ADTX Stock Symbol:
NASDAQ Market:
ADiTx Therapeutics Inc. Website:
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the Company”) (OTCQB: EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer...
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
Evofem Biosciences Inc. (OTCQB: EVFM) , a company commercializing innovative products to address unmet needs in women's sexual and reproductive health, has signed a license and supply agreement for the Middle East rights to Phexxi(R), Evofem's FDA-approved, hormone-free contra...